Reboxetine use in the treatment of attention-deficit/hyperactivity disorder.
Cak
Halime T
HT
Cetin
Füsun Cuhadaroğlu
FC
D000293:Adolescent; D000928:Antidepressive Agents / Q000009:adverse effects / Q000627:therapeutic use*; D000929:Antidepressive Agents, Tricyclic / Q000627:therapeutic use; D001289:Attention Deficit Disorder with Hyperactivity / Q000188:drug therapy* / Q000523:psychology; D000697:Central Nervous System Stimulants / Q000009:adverse effects / Q000627:therapeutic use; D002648:Child; D005260:Female; D006801:Humans; D007099:Imipramine / Q000627:therapeutic use; D008297:Male; D008774:Methylphenidate / Q000009:adverse effects / Q000627:therapeutic use; D009025:Morpholines / Q000009:adverse effects / Q000627:therapeutic use*; D000077593:Reboxetine
D000928:Antidepressive Agents; D000929:Antidepressive Agents, Tricyclic; D000697:Central Nervous System Stimulants; D009025:Morpholines; D008774:Methylphenidate; D000077593:Reboxetine; D007099:Imipramine